… of erlotinib. The Cancer and Leukemia Group B trial 30406 was a randomized phase 2 clinical
trial that investigated erlotinib … agent rather than chemotherapy for the next clinical trial. A …

… To our knowledge, this is the first phase 2 clinical trial to … with stage IIIA NSCLC in the hope
of introducing an alternative to … with chemotherapy in Chinese patients with stage IIIA EGFR …

… versus chemotherapy (etoposide/cisplatin), both with … In a phase 2 study by Lee et al, 12
which compared E + RT versus … Our study suggests that E + RT might be a beneficial alternative …

… status of 2 or lower, no previous chemotherapy for advanced … identified two phase 2 trials
that assessed the activity of erlotinib … The BELIEF study showed that combined therapy with …

… a subset analysis of an earlier trial of erlotinib plus tivantinib (a small molecule MET inhibitor),
we conducted this randomized phase 2 trial of erlotinib plus tivantinib in previously treated …

… Alternative approaches would also include aromatase inhibitors such as exemestane
alone (NCT02666105) or in combination with chemotherapy (carboplatin and pemetrexed) (…

… .3 study, two large phase III studies provided alternative first-… single-arm phase II study of
erlotinib monotherapy in patients … deemed ineligible for cytotoxic chemotherapy. At the time this …

… Clinical data in support of this trial included a phase 2 study of … refractory to chemotherapy
often still received erlotinib in the … for each comparison was 58 events under the alternative …

… this randomized Phase 2 study to evaluate the efficacy and toxicity of the combination erlotinib
and … Although this study failed to meet the primary end point, it demonstrated that patients …

… Results from a phase II study of onartuzumab plus erlotinib in … were improved compared
with placebo plus erlotinib 17 and … , with studies comparing EGFR TKIs and chemotherapy in a …